Literature DB >> 31742032

Evaluation of Multimodality Management of Adenoid Cystic Carcinoma of the Head and Neck.

Amit Bahl1, Naresh Kumar Panda2, Arun Elangovan1, Jaimanti Bakshi2, Roshan Verma2, Satyawati Mohindra2, Rijuneeta Gupta2, Arun Singh Oinam1, Satinder Kaur1, R K Vashishta3, Sushmita Ghoshal1.   

Abstract

Adenoid cystic carcinoma is a relatively rare tumour arising from salivary glands of head and neck region. Surgery and radiotherapy form standard treatment modalities in the management of this tumor. In this analysis we present results of multimodality treatment in our cohort of patient. This retrospective analysis evaluated results of treatment in forty patients diagnosed with adenoid cystic carcinoma of the head and neck. Evaluation was done to identify prognostic factors affecting the disease free survival. A median disease free survival of 34 ± 2.42 (Median ± SE) versus 10 ± 5.45 months was seen in patients undergoing surgery followed by post operative radiotherapy versus radiotherapy alone (P = 0.01). A radiotherapy dose more than 60 Gy was associated with a better disease free survival compared with patients receiving less than 60 Gy (P = 0.01). Positive surgical margins and perineural invasion were associated with a poor treatment outcome (P = 0.02) Patients with c-kit positive status showed a poor local control rate (P = 0.05). © Association of Otolaryngologists of India 2018.

Entities:  

Keywords:  Adenoid cystic; Cancer; Head and neck; Imatinib; Radiotherapy

Year:  2018        PMID: 31742032      PMCID: PMC6848353          DOI: 10.1007/s12070-018-1442-0

Source DB:  PubMed          Journal:  Indian J Otolaryngol Head Neck Surg        ISSN: 2231-3796


  18 in total

1.  Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality.

Authors:  J Fordice; C Kershaw; A El-Naggar; H Goepfert
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1999-02

2.  Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands.

Authors:  Sandrine Faivre; Eric Raymond; Odile Casiraghi; Stéphane Temam; Patrice Berthaud
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

3.  Adenoid cystic carcinoma of the head and neck: a retrospective multicenter study.

Authors:  Shinji Takebayashi; Shogo Shinohara; Hisanobu Tamaki; Ichiro Tateya; Morimasa Kitamura; Masanobu Mizuta; Shinzo Tanaka; Tsuyoshi Kojima; Ryo Asato; Toshiki Maetani; Koji Ushiro; Yoshiharu Kitani; Kazuyuki Ichimaru; Keigo Honda; Koichiro Yamada; Koichi Omori
Journal:  Acta Otolaryngol       Date:  2017-09-12       Impact factor: 1.494

Review 4.  Adenoid cystic carcinoma of the head and neck--An update.

Authors:  Andrés Coca-Pelaz; Juan P Rodrigo; Patrick J Bradley; Vincent Vander Poorten; Asterios Triantafyllou; Jennifer L Hunt; Primož Strojan; Alessandra Rinaldo; Missak Haigentz; Robert P Takes; Vanni Mondin; Afshin Teymoortash; Lester D R Thompson; Alfio Ferlito
Journal:  Oral Oncol       Date:  2015-05-02       Impact factor: 5.337

5.  Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).

Authors:  Youjin Kim; Su Jin Lee; Ji Yun Lee; Se-Hoon Lee; Jong-Mu Sun; Keunchil Park; Ho Jung An; Jae Yong Cho; Eun Joo Kang; Ha-Young Lee; Jinsoo Kim; Bhumsuk Keam; Hye Ryun Kim; Kyoung Eun Lee; Moon Young Choi; Ki Hyeong Lee; Myung-Ju Ahn
Journal:  Cancer       Date:  2017-01-19       Impact factor: 6.860

6.  Clinical prognostic factors of salivary adenoid cystic carcinoma: A single-center analysis of 61 patients.

Authors:  Robert Cordesmeyer; Henning Schliephake; Philipp Kauffmann; Markus Tröltzsch; Rainer Laskawi; Philipp Ströbel; Felix Bremmer
Journal:  J Craniomaxillofac Surg       Date:  2017-08-10       Impact factor: 2.078

7.  Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: prognostic features of recurrence.

Authors:  Allen M Chen; M Kara Bucci; Vivian Weinberg; Joaquin Garcia; Jeanne M Quivey; Naomi R Schechter; Theodore L Phillips; Karen K Fu; David W Eisele
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-01       Impact factor: 7.038

8.  Expression of KIT (CD117) in neoplasms of the head and neck: an ancillary marker for adenoid cystic carcinoma.

Authors:  M Mino; B Z Pilch; W C Faquin
Journal:  Mod Pathol       Date:  2003-12       Impact factor: 7.842

9.  Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Authors:  Charles D Blanke; George D Demetri; Margaret von Mehren; Michael C Heinrich; Burton Eisenberg; Jonathan A Fletcher; Christopher L Corless; Christopher D M Fletcher; Peter J Roberts; Daniela Heinz; Elisabeth Wehre; Zariana Nikolova; Heikki Joensuu
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

10.  Role for postoperative radiation therapy in adenoid cystic carcinoma of the head and neck.

Authors:  Damon A Silverman; Thomas P Carlson; Deepak Khuntia; Richard T Bergstrom; Jerrold Saxton; Ramon M Esclamado
Journal:  Laryngoscope       Date:  2004-07       Impact factor: 3.325

View more
  2 in total

Review 1.  Systemic therapies for salivary gland adenoid cystic carcinoma.

Authors:  Sosuke Sahara; Alexandra E Herzog; Jacques E Nör
Journal:  Am J Cancer Res       Date:  2021-09-15       Impact factor: 5.942

Review 2.  Targeted Therapy, Chemotherapy, Immunotherapy and Novel Treatment Options for Different Subtypes of Salivary Gland Cancer.

Authors:  Sarina K Mueller; Marlen Haderlein; Sebastian Lettmaier; Abbas Agaimy; Florian Haller; Markus Hecht; Rainer Fietkau; Heinrich Iro; Konstantinos Mantsopoulos
Journal:  J Clin Med       Date:  2022-01-29       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.